Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin A

Clinical Cancer Research

Volumn 5, Issue 10 SUPPL., 1999, Pages

  Richman, Carol M ^a   DeNardo, Sally J ^a   O'Donnell, Robert T ^a   Goldstein, Desiree S ^a   Shen, Sui ^a   Kukis, David L ^a   Kroger, Linda A ^a   Yuan, Aina ^a   Boniface, Graeme R ^b   Griffith, Irwin J ^b   DeNardo, Gerald L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Biomira Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID DERIVATIVE; ANTIBODY CONJUGATE; BILIRUBIN; CYCLOSPORIN A; INDIUM 111; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 170H 82 Y 90; UNCLASSIFIED DRUG; YTTRIUM 90;

ADULT; BONE MARROW SUPPRESSION; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSIMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; METASTASIS; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; THROMBOCYTOPENIA;

ADULT; ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CYCLOSPORINE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MICE; MIDDLE AGED; NEOPLASM METASTASIS; RADIOIMMUNOTHERAPY; RADIOTHERAPY DOSAGE; TRANSPLANTATION, AUTOLOGOUS; YTTRIUM RADIOISOTOPES;

EID: 0032717621     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (43)

1. DeNardo, S. J., O'Grady, L. F., Richman, C. M., and DeNardo, G. L. Overview of radioimmunotherapy in advanced breast cancer using I-131 chimeric L6. In: R. L. Ceriani. (ed.), Antigen and Antibody Molecular Engineering in Breast Cancer Diagnosis and Treatment, pp. 203-211. New York: Plenum Press, 1994.
2. Goldenberg, D. M. Monoclonal antibodies in cancer detection and therapy. Am. J. Med., 94: 297-312, 1993.
3. Meredith, R. F., Khazaeli, M. B., Liu, T., Plott, G., Wheeler, R. H., Russel, C., Colcher, D., Schlom, J., Shochat, D., and Lobuglio, A. F. Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer. J. Nucl. Med., 33: 1648-1653, 1992.
4. Wong, J. Y., Williams, L. E., Yamauchi, D. M., Odom-Maryon, T., Esteban, J. M., Neumaier, M., Wu, A. M., Johnson, D. K., Primus, F. J., and Shively, J. E. Initial experience evaluating 90yttrium-radiolabeled anti-carcinoembryonic antigen chimeric T84.66 in a Phase I radioimmunotherapy trial. Cancer Res., 55: 5929-5934, 1995.
5. Wilder, R. B., DeNardo, G. L., and DeNardo, S. J. Radioimmunotherapy: recent results and future directions. J. Clin. Oncol., 14: 1383-1400, 1996.
6. DeNardo, S. J., Mirick, G. R., Kroger, L. A., O'Grady, L. F., Erickson, K. L., Yuan, A., Lamborn, K. R., Hellstrom, I., Hellstrom, K. E., and DeNardo, G. L. The biologic window for chimeric L6 radioimmunotherapy. Cancer (Phila.), 73 (Suppl.): 1023-1032, 1994.
7. DeNardo, S. J., O'Grady, L. F., Richman, C. M., Goldstein, D. S., O'Donnell, R. T., DeNardo, D. A., Kroger, L. A., Lamborn, K. R., Hellstrom, K. E., Hellstrom, I., and DeNardo, G. L. Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody. Anticancer Res., 17: 1745-1752, 1997.
8. Press, O. W., Eary, J. F., Appelbaum, F. R., Martin, P. J., Badger, C. C., Nelp, W. B., Glenn, S., Butchko, G. M., Fisher, L. D., Porter, B., Matthews, D. C., and Bernstein, I. D. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N. Engl. J. Med., 329: 1219-1224, 1993.
9. Richman, C. M., DeNardo, S. J., O'Grady, L. F., and Fernando, L. P. Mobilized peripheral blood progenitor cell transfusion permits dose escalation of radiolabeled monoclonal antibody therapy for breast cancer. Cancer Treat. Res, 23: 183, 1992.
10. 131I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions. Cancer Res., 55 (Suppl.). 5916-5920, 1995.
11. 90Y Mx-diethylenetriamine-pentaacetic acid (DTPA)-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer: a Phase I trial. Cancer Res, 55: 5921s-5924s, 1995.
12. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet, 346: 336-340, 1995.
13. DeNardo, G. L., DeNardo, S. J., Macey, D. J., and Mills, S. L. Quantitative phamacokinetics of radiolabeled monoclonal antibodies for imaging and therapy in patients. In: S. C. Srivastava. (Ed.), Radiolabeled Monoclonal Antibodies for Imaging and Therapy, pp. 293-310. New York: Plenum Publishing Corp., 1988.
14. Shen, S., DeNardo, G. L., Macey, D. J., O'Donnell, R. T., Yuan, A., DeNardo, D. A., and DeNardo, S. J. Practical determination of organ S values for individual patients for therapy. Nucl. Med. Biol., 24: 447-449, 1997.
15. Shen, S., DeNardo, G. L., O'Donnell, R. T., Yuan, A., DeNardo, D. A., Macey, D. J., and DeNardo, S. J. Practical simplifications for radioimmunotherapy dosimetric models. In: A. T. S. Stelson, M. G. Stabin, and R. B. Sparks. (eds.), Sixth International Radiopharmaceutical Dosimetry Symposium, pp. 82-90. Oak Ridge, TN: Oak Ridge Associated Universities, 1999.
16. 90Y MAB 170H.82 with autologous stem cell support and cyclosporin A. Cancer Biother. Radiopharm., 13: 314, 1998.
17. MacLean, G. D., McEwan, A., Noujaim, A., Hooper, H., Sykes, T. R., Bodnnar, D., Lloyd, S., and Goldberg, L. Two novel monoclonal antibodies have potential for gynecologic cancer imaging. Antibody Immunoconjug. Radiopharm., 4: 297-308, 1991.
18. Alexander, C., Villena-Heinsen, C. E., Trampert, L., Lung-Kurt, S., Oberhausen, E., Kirsch, C. M., and Schmidt, W. Radioimmunoscintigraphy of ovarian tumors with technetium-99m labelled monoclonal antibody-170: first clinical experiences. Eur. J. Nucl. Med., 22: 645-651, 1995.
19. Springer, G. F. T and Tn, general carcinoma autoantigens. Science (Washington DC), 224: 1198-1206, 1984.
20. Howell, L. P., DeNardo, S. J., Levy, N., Lund, J., and DeNardo, G. L. Immunohistochemical staining of metastatic ductal carcinomas of the breast by monoclonal antibodies used in imaging and therapy: a comparative study. Int. J. Biol. Markers, 10: 126-135, 1995.
21. 111In. Nucl. Med. Commun., 13: 11-19, 1992.
22. Meares, C. F., McCall, M. J., Reardan, D. T., Goodwin, D. A., Diamanti, C. I., and McTigue, M. Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions. Anal. Biochem., 142: 68-78, 1984.
23. McCall, M. J., Diril, H., and Meares, C. F. Simplified method for conjugating macrocyclic bifunctional chelating agents to antibodies via 2-iminothiolane. Bioconjug. Chem., 1: 222-226, 1990.
24. 67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma. J. Nucl. Med., 40: 302-310, 1999.
25. DeNardo, S. J., Zhong, G.-R., Salako, Q., Li, M., DeNardo, G. L., and Meares, C. F. Pharmacokinetics of chimeric L6 conjugated to indium-111 and yttrium-90-DOTA-peptide in tumor bearing mice. J. Nucl. Med., 36: 829-836, 1995.
26. Kukis, D. L., DeNardo, G. L., DeNardo, S. J., Mirick, G. R., Miers, L. A.. Greiner, D. P., and Meares, C. F. Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates. Cancer Res., 55: 878-884, 1995.
27. Beaumier, P. L., Neuzil, D., Yang, H. M., Noll, E. A., Kishore, R., Eary, J. F., Krohn, K. A., Nelp, W. B., Hellstrom, K. E., and Hellstrom, I. Immunoreactivity assay for labeled anti-melanoma monoclonal antibodies. J. Nucl. Med., 27: 824-828, 1986.
28. DeNardo, S. J., O'Grady, L. F., Macey, D. J., Kroger, L. A., DeNardo, G. L., Lamborn, K. R., Levy, N. B., Mills, S. L., Hellstrom, I., and Hellstrom, K. E. Quantitative imaging of mouse L-6 monoclonal antibody in breast cancer patients to develop a therapeutic strategy. Int. J. Radiat. Appl. Instrum. B, 18: 621-631, 1991.
29. Loevinger, R., and Berman, M. A revised schema for calculating the absorbed dose from biologically distributed radionuclides, pp. 1-10. MIRD Pamphlet No. 1. New York: Society of Nuclear Medicine, 1976.
30. Snyder, W. S., Ford, M. R., and Warner, G. G. 'S' absorbed dose per unit cumulated activity for selected radionuclides and organs, pp. 82-83. MIRD Pamphlet No. 11. New York: Society of Nuclear Medicine, 1975.
31. DeNardo, S. J., DeNardo, G. L., O'Grady, L. F., Hu, E., Sytsma, V. M., Mills, S. L., Levy, N. B., Macey, D. J., Miller, C. H., and Epstein, A. L. Treatment of B cell malignancies with I-131 Lym-1 monoclonal antibodies. Int. J. Cancer, 3 (Suppl.): 96-101, 1988.
32. DeNardo, S. J., Richman, C. M., Goldstein, D. S., Shen, S., Salako, Q. A., Kukis, D. L., Meares, C. F., Yuan, A., Welborn, J. L., and DeNardo, G. L. Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer. Anticancer Res., 17: 1735-1744, 1997.
33. 111In-labeled monoclonal antitumor antibodies in normal animals and nude-mouse human tumor models. Cancer Res., 43: 5347-5355, 1983.
34. Pimm, M. V., Perkin, A. C., and Baldwin, R. W. Differences in tumor and normal tissue concentrations of iodine and indium labeled monoclonal antibody. II. Biodistribution studies in mice with human tumor xenografts. Eur. J. Nucl. Med., 11: 300-304, 1985.
35. Larson, S. M., and Carrasquillo, J. A. Advantages of radioiodine over radioindium labeled monoclonal antibodies for imaging solid tumors. Nucl. Med. Biol., 15: 231-233, 1988.
36. DeNardo, S. J., DeNardo, G. L., O'Grady, L. F., Levy, N. B., Mills, S. L., Macey, D. J., McGahan, J. P., Miller, C. H., and Epstein, A. L. Pilot studies of radioimmunotherapy of B cell lymphoma and leukemia using I-131 Lym-1 monoclonal antibody. Antibody Immunoconjug. Radiopharm., 1: 17-33, 1988.
37. Schlom, J., Molinolo, A., Simpson, J. F., Siler, K., Roselli, M., Hinkle, G., Houchens, D. P., and Colcher, D. Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy. J. Natl. Cancer Inst., 82: 763-771, 1990.
38. 67Cu- 2IT-BAT-Lym-1 and opportunities for improvement. In: D. M. Goldenberg (Ed.), Cancer Therapy with Radiolabeled Antibodies, pp. 217-227. Boca Raton, FL: CRC Press, 1994.
39. Ledermann, J. A., Begent, R. H., Massof, C., Kelly, A. M., Adam, T., and Bagshawe, K. D. A Phase I study of repeated therapy with radiolabeled antibody to carcinoembryonic antigen using intermittent or continuous administration of cyclosporin A to suppress the immune response. Int. J. Cancer, 47: 659-664, 1991.
40. Weiden, P. L., Wolf, S. B., Breitz, H. B., Appelbaum, J. W., Seiler, C. A., Mallett, R., Bjorn, M. J., Su, F. M., Fer, M. F., and Salk, D. Human anti-mouse antibody suppression with cyclosporin A. Cancer (Phila.), 73: 1093-1097, 1994.
41. DeNardo, G. L., Kroger, L. A., Meares, C. F., Richman, C. M., Salako, Q. A., Shen, S., Lamborn, K. R., Peterson, J. J., Miers, L. A., Zhong, G. R., and DeNardo, S. J. Comparison of DOTA-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2IT-BAD-ChL6 in breast cancer xenografts. Clin. Cancer Res., 4: 2483-2490, 1998.
42. DeNardo, S. J., Kukis, D. L., Kroger, L. A., O'Donnell, R. T., Lamborn, K. R., Miers, L. A., DeNardo, D. G., Meares, C. F., and DeNardo, G. L. Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts. Proc. Natl. Acad. Sci. USA, 94: 4000-4004, 1997.
43. DeNardo, S. J., Richman, C. M., Kukis, D. L., Shen, S., Lamborn, K. R., Miers, L. A., Kroger, L. A., and DeNardo, G. L. Synergistic therapy for breast cancer: development of a clinical protocol for RIT and Taxol based on curative therapy of xenografted tumors and Y-90 ChL6 patient dosimetry. J. Nucl. Med., 39: 246, 1998.